## Edgar Filing: AbbVie Inc. - Form 4

AbbVie Inc

Form 4 May 13, 2014											
May 13, 2014									OMB APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check this if no longe subject to Section 16 Form 4 or	er <b>STATEM</b>	ENT O	ENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							January 31, 2005 average Irs per 0.5	
Form 5 obligation may contin <i>See</i> Instruct 1(b).	s Section 17(a	) of the		ility Hold	ing Com	pany	Act o	ge Act of 1934, f 1935 or Sectio 40	response n		
(Print or Type R	esponses)										
1. Name and Address of Reporting Person _2. IssueWADDELL FREDERICK HSymbol				uer Name <b>and</b> Ticker or Trading l				5. Relationship of Reporting Person(s) to Issuer			
A				Inc. [AB]	BV]			(Check all applicable)			
(Last)(First)(Middle)3. Date of (Month/Date)1 N. WAUKEGAN ROAD05/09/20				•				X_ Director 10% Owner Officer (give title Other (specify below) below)			
				ndment, Date Original hth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NORTH CH	ICAGO, IL 6006	4						Form filed by M Person	Iore than One Ro	eporting	
(City)	(State) (	Zip)	Table	e I - Non-De	erivative S	Securi	ties Ac	quired, Disposed of	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	med 3. 4. Securities on Date, if TransactionAcquired (A) or Code Disposed of (D) Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)		))	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code V	Amount	or	Price	Transaction(s) (Instr. 3 and 4)			
Common stock, \$0.01 par value	05/09/2014			A <u>(1)</u>	2,764	А	\$ 0 (1)	7,299	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: AbbVie Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr
				Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh		
	Director	10% Owner	Officer	Other
WADDELL FREDERICK H 1 N. WAUKEGAN ROAD NORTH CHICAGO, IL 60064	Х			
Signatures				
Steven L. Scrogham, attorney-in	n-fact for	Frederick H	•	05/13/2014

en L. Scrognam, attorney-in-fact for Frederick H. Waddell

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a (1) one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the

occurrence of a change in control (as defined in the Program).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.